Google
NAUT — NAUTILUS BIOTECHNOLOGY INC (Healthcare >> Biotechnology)
NAUT FAQ
What is NAUT's ROE?
NAUTILUS BIOTECHNOLOGY INC reports a Return on Equity (ROE) of -39.53%.
What is NAUT's dividend yield?
NAUTILUS BIOTECHNOLOGY INC offers a dividend yield of 0.00%.
What is NAUT's Deepscope Quality Score?
Deepscope rates NAUT's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NAUT?
Deepscope's AI Timing Score for NAUT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NAUT belong to?
NAUTILUS BIOTECHNOLOGY INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.39
Price
-0.29
(-10.82%)
Day Change
|
|
|---|
NAUT, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.39 |
| PBV / Sector |
2.36 / 4.63
|
| Earning Per Share | -0.40 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
1.22 M
GREAT
|
| Average 1W Daily Value |
1.13 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:04 |
| Symbol | NAUT |
| Name | NAUTILUS BIOTECHNOLOGY INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 127.08 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 340.57 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2701 Eastlake Avenue East, Seattle, WA, United States, 98102
Phone: 206 333 2001
Website: https://www.nautilus.bio
Employees: 127
Sector: Healthcare >> Biotechnology
Description: Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
